Search from website

Human IgG1-kappa antibody to SARS CoV-2 S1 RBD (clone 6G7)

 

Figure 1. Coomassie-stained SDS-PAGE analysis of monoclonal antibody to SARS-CoV-2 Spike RBD, clone 6G7. 4-12% gradient gel is used for analysis. Lane 1. Monoclonal antibody to SARS-CoV-2 Spike RBD, clone 6G7 (-DTT). Lane 2. Size marker. Lane 3. Monoclonal antibody to SARS-CoV-2 Spike RBD, clone 6G7 (+DTT). Lane 4. Size marker.

       

Figure 2. HPLC analytical SEC for final product.

       

Figure 3. HPLC analytical SEC after 3 freeze-thaw cycles.

       

Figure 4. Octet RED96e analysis, antibody was loaded on sensor for capture of Spike S1 protein in different concentrations: 200 nM, 100 nM and 50 nM.

Select volume:

Quantity:

Catalogue #

R1-151-100

Name

Human IgG1-kappa antibody to SARS CoV-2 S1 RBD (clone 6G7)

Target

SARS-CoV-2 virus

Target Description

SARS-CoV-2 virus (PBMCs isolated from patients recovered from SARS-CoV-2 infection, antibodies discovered by using HybriFree Technology).

Clonality

Human monoclonal

Clone

6G7

Class

hIgG1

Reactivity

SARS-CoV-2 Spike RBD
Neutralizing properties: blocks S1 and ACE2 binding in Octet system; IC50 5000 ng/ml measured in live virus neutralization assay

Dissociation constant (KD)

< 1.0 x 10-12 M (measured against SARS-CoV-2 Trimeric Spike protein)

1.66 x 10-8 M (measured against SARS-CoV-2 Spike S1 protein)

Application

ELISA

ELISA:

0,08-0,16 ng/ml

Purification

Protein A affinity chromatography following desalting

Buffer

PBS pH 7.4

Shipping

Shipped at ambient temperature.

Storage

Store at -20 °C to -70 °C long term. Avoid multiple freeze-thaw cycles.

This product is for research use only

TECHNICAL ASSISTANCE

Please refer any technical questions to

technical.support@icosagen.com

Our locations

United States Office

77 Geary St. 5th Floor
San Francisco, CA 94108
+1 415 548 6625

European Office

Eerika tee 1
Õssu, Kambja vald
Tartu maakond 61713
Estonia
+372 737 7070
error:
Shopping Cart